This Plain Language Summary of Publication article (PLSP) from Future Oncology examined patients over approximately 5 years and found that those receiving D-VRd showed better outcomes than those on VRd alone, with more achieving complete remission and living longer without disease progression. While D-VRd caused slightly more side effects (particularly infections), both treatments had manageable and expected side effects for these types of medications.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial’ and was published in Nature Medicine.

Visit Nature using the link to read the original article.